J&J Expects Procrit Stability Under Medicare Average Sales Price Model
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite volume gains, Procrit sales slumped 12% over the year due to pricing pressue. The growing EPO market coupled with pricing stability under Medicare Part B offers an opportunity for Procrit growth in 2005, Johnson & Johnson Worldwide Chairman Poon says.